AIM ImmunoTech Profitability Analysis

AIM Stock  USD 0.23  0.02  9.52%   
Considering the key profitability indicators obtained from AIM ImmunoTech's historical financial statements, AIM ImmunoTech may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess AIM ImmunoTech's ability to earn profits and add value for shareholders.
 
Net Loss  
First Reported
1995-01-31
Previous Quarter
-1.8 M
Current Value
-3.7 M
Quarterly Volatility
1.7 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, AIM ImmunoTech's Days Sales Outstanding is very stable compared to the past year. As of the 28th of November 2024, Sales General And Administrative To Revenue is likely to grow to 109.87, while EV To Sales is likely to drop 78.31. At this time, AIM ImmunoTech's Total Other Income Expense Net is very stable compared to the past year. As of the 28th of November 2024, Net Interest Income is likely to grow to about 759.5 K, though Income Before Tax is likely to grow to (27.5 M).
For AIM ImmunoTech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of AIM ImmunoTech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well AIM ImmunoTech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between AIM ImmunoTech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of AIM ImmunoTech over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.48)
Revenue Per Share
0.004
Quarterly Revenue Growth
0.19
Return On Assets
(0.80)
Return On Equity
(1.55)
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

AIM ImmunoTech Return On Asset vs. Return On Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining AIM ImmunoTech's current stock value. Our valuation model uses many indicators to compare AIM ImmunoTech value to that of its competitors to determine the firm's financial worth.
AIM ImmunoTech is rated fourth in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, AIM ImmunoTech's Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value AIM ImmunoTech by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

AIM Return On Asset vs. Return On Equity

Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

AIM ImmunoTech

Return On Equity

 = 

Net Income

Total Equity

 = 
-1.55
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

AIM ImmunoTech

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.8
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

AIM Return On Asset Comparison

AIM ImmunoTech is currently under evaluation in return on asset category among its peers.

AIM ImmunoTech Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in AIM ImmunoTech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, AIM ImmunoTech will eventually generate negative long term returns. The profitability progress is the general direction of AIM ImmunoTech's change in net profit over the period of time. It can combine multiple indicators of AIM ImmunoTech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Operating Income-31.9 M-30.3 M
Income Before Tax-29 M-27.5 M
Total Other Income Expense NetM3.1 M
Net Loss-29 M-27.5 M
Income Tax Expense1.9 M1.3 M
Net Interest Income723.4 K759.5 K
Interest Income723.4 K759.5 K
Net Loss-17.5 M-18.4 M
Net Loss(0.60)(0.63)
Income Quality 0.73  0.67 
Net Income Per E B T 0.98  0.83 

AIM Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on AIM ImmunoTech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of AIM ImmunoTech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the AIM ImmunoTech's important profitability drivers and their relationship over time.

AIM ImmunoTech Profitability Trends

AIM ImmunoTech profitability trend refers to the progression of profit or loss within a business. An upward trend means that AIM ImmunoTech's profit has generally increased over time, and a downward profitability trend means profits are declining. Recognizing problems early in profitability trends allows investors to address revenue and cost issues in advance. Investors and analysts usually monitor three types of profitability trends: gross, operating, and net. Gross profit is the difference between revenue and costs of goods sold. Operating profit is AIM ImmunoTech's gross profit minus its overhead. After you account for other unusual revenue, expenses, and costs, you get net profit. Gross profit trends are often a good indicator of future profitability. If you have high gross profit margins, you have a better chance to cover overhead and make money.

AIM ImmunoTech Profitability Drivers Correlations

One of the toughest challenges investors face today is learning how to quickly synthesize and read into endless financial statements and information provided by the company, SEC reporting, and various external parties. Understanding the correlation between AIM ImmunoTech different financial indicators related to revenue and profit generation helps investors identify and prioritize their investing strategies towards AIM ImmunoTech in a much-optimized way. Analyzing correlations between profit drivers that are directly associated with dollar figures is the most effective way to break down AIM ImmunoTech's future profitability.

Use AIM ImmunoTech in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AIM ImmunoTech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AIM ImmunoTech will appreciate offsetting losses from the drop in the long position's value.

AIM ImmunoTech Pair Trading

AIM ImmunoTech Pair Trading Analysis

The ability to find closely correlated positions to AIM ImmunoTech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AIM ImmunoTech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AIM ImmunoTech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AIM ImmunoTech to buy it.
The correlation of AIM ImmunoTech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AIM ImmunoTech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AIM ImmunoTech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AIM ImmunoTech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your AIM ImmunoTech position

In addition to having AIM ImmunoTech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Robots And Drones Thematic Idea Now

Robots And Drones
Robots And Drones Theme
Large technology companies that are involved in development and manufacturing of drones, robots, or robotic equipment across mechanical engineering, electrical engineering, mathematics and computer science fields. Drones and robotics are projected to significantly grow in demand in the next 5 years. The Robots And Drones theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Robots And Drones Theme or any other thematic opportunities.
View All  Next Launch
When determining whether AIM ImmunoTech is a strong investment it is important to analyze AIM ImmunoTech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact AIM ImmunoTech's future performance. For an informed investment choice regarding AIM Stock, refer to the following important reports:
Check out Trending Equities.
To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.
You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
To fully project AIM ImmunoTech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of AIM ImmunoTech at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include AIM ImmunoTech's income statement, its balance sheet, and the statement of cash flows.
Potential AIM ImmunoTech investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although AIM ImmunoTech investors may work on each financial statement separately, they are all related. The changes in AIM ImmunoTech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on AIM ImmunoTech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.